Valuation: Agenus Inc.

Market Cap 142M 124M 115M 106M 202M 13.48B 205M 1.37B 534M 6.65B 533M 522M 22.99B P/E 2026 *
4.34x
P/E 2027 * -18.9x
Enterprise Value 142M 124M 115M 106M 202M 13.48B 205M 1.37B 534M 6.65B 533M 522M 22.99B EV / Sales 2026 *
0.77x
EV / Sales 2027 * 1.08x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -
1 day+3.52%
1 week+14.05%
Current month+14.05%
1 month+11.15%
3 months-14.04%
6 months-5.68%
Current year+11.15%
1 week 3.06
Extreme 3.06
3.58
1 month 2.85
Extreme 2.85
3.58
Current year 2.71
Extreme 2.71
5.08
1 year 2.71
Extreme 2.71
7.34
3 years 1.38
Extreme 1.38
38.6
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Chief Executive Officer

5,364 0.0129%
06-12Free

Chief Executive Officer

4,925 0.0118%
05-29Free

Chief Executive Officer

4,644 0.0112%
Change 5-day change 1-year change 3-year change Capi.($)
+3.52%+14.05%-32.63%-89.36% 142M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.84%+2.62%+424.10%+628.26% 40.39B
+1.18%+8.02%+28.47%-3.74% 34.38B
-0.64%+7.57%+27.21%+61.73% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+0.97%+1.59% - - 16.64B
-2.35%+4.53%+73.58%+135.03% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.63%+8.84%+106.55%+106.55% 13.75B
Average +0.82%+5.39%+72.19%+100.36% 24.61B
Weighted average by Cap. +0.36%+4.11%+96.61%+142.33%

Financials

2026 *2027 *
Net sales 185M 162M 149M 138M 262M 17.53B 266M 1.79B 695M 8.65B 693M 678M 29.9B 131M 115M 106M 98.26M 187M 12.48B 190M 1.27B 494M 6.16B 494M 483M 21.28B
Net income 46M 40.25M 37.1M 34.39M 65.28M 4.37B 66.33M 445M 173M 2.15B 173M 169M 7.45B -9.9M -8.66M -7.98M -7.4M -14.05M -940M -14.27M -95.74M -37.23M -464M -37.17M -36.36M -1.6B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
07/07/26 $3.490 +2.35% 618,330
06/07/26 $3.410 -2.29% 548,115
02/07/26 $3.490 +2.35% 680,579
01/07/26 $3.410 +11.44% 660,413
30/06/26 $3.060 -2.86% 644,548
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.410USD
Average target price
15.50USD
Spread / Average Target
+354.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock